{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,26]],"date-time":"2026-08-26T10:30:52Z","timestamp":1787740252789,"version":"build-2784847793"},"reference-count":15,"publisher":"BMJ","issue":"1","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["5P30- CA023074"],"award-info":[{"award-number":["5P30- CA023074"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["j. immunotherapy cancer"],"published-print":{"date-parts":[[2017,12]]},"DOI":"10.1186\/s40425-017-0263-0","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T13:32:45Z","timestamp":1499779965000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":103,"title":["Angiosarcoma treated successfully with anti-PD-1 therapy - a case report"],"prefix":"10.1136","volume":"5","author":[{"given":"Simran","family":"Sindhu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lana H.","family":"Gimber","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lee","family":"Cranmer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ali","family":"McBride","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew S.","family":"Kraft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"239","published-online":{"date-parts":[[2017,7,18]]},"reference":[{"key":"263_CR1","doi-asserted-by":"crossref","first-page":"524","DOI":"10.1097\/01.coc.0000227544.01779.52","volume":"29","author":"WM Mendenhall","year":"2006","unstructured":"Mendenhall WM, Mendenhall CM, Werning JW, et al. Cutaneous Angiosarcoma. Am J Clin Oncol. 2006;29:524\u20138.","journal-title":"Am J Clin Oncol"},{"key":"263_CR2","doi-asserted-by":"crossref","first-page":"5269","DOI":"10.1200\/JCO.2008.17.3146","volume":"26","author":"N Penel","year":"2008","unstructured":"Penel N, Bui BN, Bay JO, et al. Phase II trial of weekly paclitaxel for unresectable angiosarcoma: the ANGIOTAX study. J Clin Oncol. 2008;26:5269\u201374.","journal-title":"J Clin Oncol"},{"key":"263_CR3","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1038\/nrclinonc.2014.26","volume":"11","author":"M Linch","year":"2014","unstructured":"Linch M, Miah AB, Thway K, et al. Systemic treatment of soft-tissue sarcoma-gold standard and novel therapies. Nat Rev Clin Oncol. 2014;11:187\u2013202.","journal-title":"Nat Rev Clin Oncol"},{"key":"263_CR4","doi-asserted-by":"crossref","first-page":"1127","DOI":"10.1259\/bjr\/31655219","volume":"85","author":"K Ogawa","year":"2012","unstructured":"Ogawa K, Takahashi K, Asato Y, et al. Treatment and prognosis of angiosarcoma of the scalp and face: a retrospective analysis of 48 patients. Br J Radiol. 2012;85:1127\u201333.","journal-title":"Br J Radiol"},{"key":"263_CR5","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1001\/jamaoto.2014.3584","volume":"141","author":"SH Patel","year":"2015","unstructured":"Patel SH, Hayden RE, Hinni ML. Angiosarcoma of the scalp and face: the Mayo Clinic experience. Otolaryngol Head Neck Surg. 2015;141:335\u201340.","journal-title":"Otolaryngol Head Neck Surg"},{"key":"263_CR6","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1097\/00007890-199709150-00001","volume":"64","author":"I Penn","year":"1997","unstructured":"Penn I. Kaposi\u2019s sarcoma in transplant recipients. Transplantation. 1997;64:669\u201373.","journal-title":"Transplantation"},{"key":"263_CR7","doi-asserted-by":"crossref","first-page":"1485","DOI":"10.1097\/00007890-199560120-00020","volume":"60","author":"I Penn","year":"1995","unstructured":"Penn I. Sarcomas in organ allograft recipients. Transplantation. 1995;60:1485\u2013149.","journal-title":"Transplantation"},{"key":"263_CR8","doi-asserted-by":"crossref","first-page":"3182","DOI":"10.1158\/1078-0432.CCR-15-2550","volume":"22","author":"MS Merchant","year":"2016","unstructured":"Merchant MS, Bernstein D, Amoako M, et al. Adjuvant immunotherapy to improve outcome in high-risk pediatric sarcomas. Clin Cancer Res. 2016;22:3182\u201391.","journal-title":"Clin Cancer Res"},{"key":"263_CR9","doi-asserted-by":"crossref","first-page":"34","DOI":"10.2353\/ajpath.2010.090637","volume":"17","author":"J Manner","year":"2010","unstructured":"Manner J, Radwimmer B, Hohenberger P, et al. MYC high level gene amplification is a distinctive feature of angiosarcomas after irradiation or chronic lymphedema. Am J Pathol. 2010;17:34\u20139.","journal-title":"Am J Pathol"},{"key":"263_CR10","doi-asserted-by":"crossref","first-page":"509","DOI":"10.1038\/modpathol.2013.163","volume":"4","author":"W Shon","year":"2014","unstructured":"Shon W, et al. MYC amplification and overexpression in primary cutaneous angiosarcoma: a fluorescence in-situ hybridization and immunohistochemical study. Mod Pathol. 2014;4:509\u201315.","journal-title":"Mod Pathol"},{"key":"263_CR11","first-page":"168145","volume":"2013","author":"RG Maki","year":"2013","unstructured":"Maki RG, Jungbluth AA, Gnjatic S, et al. A pilot study of anti-CTLA4 antibody ipilimumab in patients with synovial sarcoma. Sarcoma. 2013;2013:168145.","journal-title":"Sarcoma"},{"key":"263_CR12","doi-asserted-by":"crossref","first-page":"e82870","DOI":"10.1371\/journal.pone.0082870","volume":"8","author":"JR Kim","year":"2013","unstructured":"Kim JR, Moon YJ, Kwon KS, et al. Tumor infiltrating PD1positive lymphocytes and the expression of PD-L1 predict poor prognosis of soft tissue sarcomas. PLoS One. 2013;8:e82870.","journal-title":"PLoS One"},{"key":"263_CR13","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1016\/j.humpath.2014.11.001","volume":"46","author":"SP D\u2019Angelo","year":"2015","unstructured":"D\u2019Angelo SP, Shoushtari AN, Agaram NP, et al. Prevalence of tumor-infiltrating lymphocytes and PD-L1 expression in the soft tissue sarcoma microenvironment. Hum Pathol. 2015;46:357\u201365.","journal-title":"Hum Pathol"},{"key":"263_CR14","doi-asserted-by":"crossref","unstructured":"Tawbi H et al. Safety and efficacy of PD-1 blockade using pembrolizumab in patients with advanced soft issue (STS) and bone sarcomas (BS): Results of SARC028- A multicenter phase II study. Presented at: ASCO 2016, Annual Meeting of The American Society of Clinical Oncology, June 3\u20137, The American Society of Clinical Oncology, Chicago, Abstract 11006. 2016.","DOI":"10.1200\/JCO.2016.34.15_suppl.11006"},{"key":"263_CR15","doi-asserted-by":"crossref","unstructured":"Paoluzzi L, et al. Anti-PD1 therapy with nivolumab in sarcoma. Presented at: ASCO 2016, Annual Meeting of The American Society of Clinical Oncology, June 3\u20137, The American Society of Clinical Oncology, Chicago, Abstract 11047. 2016.","DOI":"10.1093\/annonc\/mdw388.06"}],"container-title":["Journal for ImmunoTherapy of Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s40425-017-0263-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,9,25]],"date-time":"2020-09-25T17:42:43Z","timestamp":1601055763000},"score":1,"resource":{"primary":{"URL":"https:\/\/jitc.bmj.com\/lookup\/doi\/10.1186\/s40425-017-0263-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,7,18]]},"references-count":15,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2017,12]]}},"alternative-id":["263"],"URL":"https:\/\/doi.org\/10.1186\/s40425-017-0263-0","relation":{},"ISSN":["2051-1426"],"issn-type":[{"value":"2051-1426","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,7,18]]},"article-number":"58"}}